Princeton, NJ, October 24, 2024 - PRISM MediaWire - Soligenix, Inc. (Nasdaq: SNGX) (“Soligenix” or the “Company”) a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, today announced that it will be participating in The ThinkEquity Conference on October 30, 2024, at the Mandarin Oriental Hotel in New York. The ThinkEquity Conference gathers institutional investors, corporate clients, and other...
NEWSROOM
Biotechnology
Adial Pharmaceuticals to Present at the 2024 ThinkEquity Conference
Glen Allen, VA, October 23, 2024 - PRISM MediaWire - Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced that it will be participating in The ThinkEquity Conference on October 30, 2024, at the Mandarin Oriental Hotel in New York. The ThinkEquity Conference gathers institutional investors, corporate clients, and other...
NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) and HOPE Therapeutics, Inc. Announce Participation at the ThinkEquity Conference October 30, 2024
MIAMI, FL., October 23, 2024 – PRISM MediaWire - NRx Pharmaceuticals, Inc. (Nasdaq: NRXP), a clinical-stage biopharmaceutical company, (“NRx,” the “Company”) and HOPE Therapeutics, Inc., a medical and technology driven company and wholly-owned subsidiary of NRx, today announced they will be featured as a participating in the ThinkEquity Conference on October 30, 2024, at the Mandarin Oriental Hotel in New York. The ThinkEquity Conference gathers institutional investors, corporate...
Dr. Makoto Kuro-o, Pioneer of the Klotho Anti-Aging Gene, Joins Klotho Neurosciences, Inc. as Scientific Advisor
Discoverer of Klotho gene further strengths KLTO Scientific Advisory Board New York, NY, October 23, 2024 - PRISM MediaWire - Klotho Neurosciences, Inc. (NASDAQ: KLTO), a leading biotechnology company focused on developing cell and gene therapies for aging and age-related diseases, is proud to announce the appointment of Dr. Makoto Kuro-o to its Scientific Advisory Board. Dr. Kuro-o, a distinguished Japanese physician-scientist, is widely recognized as the pioneer behind the discovery of the...
BioStem Technologies Reports Breakthrough Results in a Diabetic Foot Ulcer Wound Closure Study Comparing BioREtain® to Standard of Care Treatment
Retrospective Study demonstrates clinical efficacy and statistical support for tissue processed via BioREtain to care for treatment-resistant chronic wounds Study published in the peer-reviewed journal, ‘International Wound Journal’ POMPANO BEACH, Fla., Oct. 17, 2024 - PRISM MediaWire - BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived biologics for advanced wound care, announces breakthrough...
Oncocyte Announces Participation in the LD Micro Main Event XVII Conference in Los Angeles
IRVINE, Calif., Oct. 16, 2024 - PRISM MediaWire - Oncocyte Corp. (NASDAQ: OCX), a diagnostics technology company, announced today that CEO Josh Riggs is scheduled to present at the 17th annual Main Event, hosted by LD Micro, on Tuesday, October 29th in Los Angeles. Oncocyte management will also be available for one-on-one meetings with investors. To schedule a one-on-one meeting, please contact Julie Silber at PCG Advisory (jsilber@pcgadvisory.com) or request a meeting via the LD Micro...
Join the Biofuels Brazil Forum 2024!
Biofuels Brazil Forum 2024 Join the Biofuels Brazil Forum 2024! New York, October 15, 2024 - We are pleased to announce that PRISM Mediawire will be one of the official Media partners for the upcoming International Investment Forum Biofuels Brazil 2024, which will take place from November 27 to 28, 2024, in São Paulo, Brazil. This forum is the premier platform for biofuel producers, regulatory bodies, government officials, technology pioneers, equipment suppliers, engineering companies, and...
BioStem Technologies Establishes National Pricing for Vendaje AC® from the Center for Medicare Services and Provides Reimbursement in All MAC Regions
Vendaje AC to launch across MAC regions nationwide through Venture Medical, the Company’s exclusive sales and marketing partner for AmnioWrap2® POMPANO BEACH, Fla., Oct. 15, 2024 - PRISM MediaWire - BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacture, and commercialization of placental-derived biologics for advanced wound care, today announced that the Center for Medicare Services (CMS) has established national pricing for its allograft...
Co-Founder of Shire Pharmaceuticals Appointed as Chief Operating Officer of Klotho Neurosciences
KLTO strengthens team with industry veteran and is poised to accelerate the development of its therapeutic candidates New York, NY, October 15, 2024 - PRISM MediaWire - Klotho Neurosciences, Inc. (NASDAQ: KLTO), a U.S.-based biotechnology company pioneering cell and gene therapies for aging and age-related diseases, today announced the appointment of Peter Moriarty, Co-Founder of Shire Pharmaceuticals, as its Chief Operating Officer (COO). “We are thrilled to have Peter join Klotho...
Lipella Pharmaceuticals Announces U.S. Patent Allowance for Innovative Liposomal Drug Delivery Platform
Patent application covers key technology innovations for delivering therapeutic agents Proprietary technology enables precise delivery to improve safety and efficacy in oncology, cancer survivorship and immunotherapy Allowance provides broad IP protection for drug-delivery platform and extends market exclusivity for two lead clinical assets currently in Phase 2 trials PITTSBURGH, PA, October 15, 2024 - PRISM MediaWire - Lipella Pharmaceuticals Inc. (Nasdaq: LIPO), a clinical-stage...
Lipella Pharmaceuticals to Present at 2024 Maxim Healthcare Virtual Summit
PITTSBURGH, Oct. 09, 2024 - PRISM MediaWire - Lipella Pharmaceuticals, Inc. (Nasdaq: LIPO) (“Lipella” or the “Company”), a clinical-stage biotechnology company focused on addressing serious diseases with significant unmet needs, today announced that CEO Jonathan Kaufman, PhD will be presenting at the 2024 Maxim Healthcare Virtual Summit that is being held on October 15 -17, 2024. Event: Lipella Presentation - 2024 Maxim Healthcare Virtual Summit Date: Thursday, October 17th, 2024...
Oncocyte’s DetermaIO Immuno-Oncology Assay Predicts Response to Atezolizumab in Phase 2 Clinical Trial
Results published in peer-reviewed journal, Clinical Cancer Research Study validates DetermaIO’s utility in identifying breast cancer patients most likely to benefit from atezolizumab DetermaIO targets a multi-billion-dollar addressable market in oncology diagnostics IRVINE, Calif., October 8, 2024 - PRISM MediaWire - Oncocyte Corp. (Nasdaq: OCX), a diagnostics technology company, announced the peer-reviewed publication of positive data related to its proprietary gene expression test,...
Entrevista exclusiva com Newton Santana, Presidente e Diretor da BEVAP Bioenergia, em antecipação ao Biocombustíveis Brasil 2024
London, October 5, 2024 - PRISM MediaWire - Temos o prazer de compartilhar uma entrevista exclusiva com Newton Santana, Presidente e Diretor da BEVAP Bioenergia, em antecipação ao Biocombustíveis Brasil 2024 que acontecerá nos dias 27 e 28 de novembro em São Paulo. Newton Santana, Presidente e Diretor da BEVAP Bioenergia Nesta conversa perspicaz, Newton revela as estratégias de ponta da BEVAP para manter a liderança em inovação e sustentabilidade, ao mesmo tempo que oferece uma perspectiva...
Exclusive interview with Newton Santana, President and Director of BEVAP Bioenergy, ahead of Biofuels Brazil 2024
London, October 5, 2024 - PRISM MediaWire - We are pleased to share an exclusive interview with Newton Santana, President and Director of BEVAP Bioenergy, ahead of Biofuels Brazil 2024, which will take place on November 27-28 in São Paulo. Newton Santana, President and Director of BEVAP Bioenergy In this insightful conversation, Newton reveals BEVAP's cutting-edge strategies to maintain leadership in innovation and sustainability while offering a glimpse into the future of the biofuels...
Entrevista exclusiva con Newton Santana, Presidente y Director de BEVAP Bioenergía, en anticipación a Biocombustibles Brasil 2024
Londres, October 5, 2024 - PRISM MediaWire - Nos complace compartir una entrevista exclusiva con Newton Santana, Presidente y Director de BEVAP Bioenergía, en anticipación a Biocombustibles Brasil 2024, que se llevará a cabo los días 27 y 28 de noviembre en São Paulo. Newton Santana, Presidente y Director de BEVAP Bioenergía En esta conversación perspicaz, Newton revela las estrategias de vanguardia de BEVAP para mantener el liderazgo en innovación y sostenibilidad, al mismo tiempo que ofrece...
Oncocyte Corporation Announces $10.2 Million Private Placement of Securities Priced At-The-Market Under Nasdaq Rules
Company Obtains Participation from New and Existing Investors, Including Strategic Partner Bio-Rad Laboratories IRVINE, Calif., Oct. 02, 2024 - Oncocyte Corporation (Nasdaq: OCX) (“Oncocyte” or the “Company”), a diagnostics technology company, today announced that it has entered into a securities purchase agreement (the “Purchase Agreement”) with new and existing investors, including Bio-Rad Laboratories, Inc., one of the Company’s strategic partners. The gross proceeds to the Company from the...
BioStem Technologies Initiates BR-AC-DFU-101 Clinical Trial to Study BioREtain® in Diabetic Foot Ulcers
Strategic head-to-head study of BR-AC vs. standard of care aims to demonstrate healing superiority potential to support increased payor coverage and market growth The study will be conducted in 60 patients at 10 sites across the U.S. and the first patients have begun treatment POMPANO BEACH, Florida, October 2, 2024 - BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacture, and commercialization of placental-derived biologics for advanced wound...
Halberd & Athena GTX Report Initial Success of WatchDawg® PTSD Treatment Pilot Study
Ten Military Veteran Volunteers Participated in the Pilot Study Enabled by Athena GTX Health Monitoring System Jackson Center, PA, October 1, 2024 – PRISM MediaWire - Halberd Corporation (OTC PINK: HALB) released the results of the recently completed WatchDawg® Pilot Study. Ten (10) military veterans participated in the study where they received pharmaceuticals (LDX) and nutraceuticals, along with 24/7 access to mental health therapies provided by Yogani/Exalted Warrior Foundation....
BioStem Technologies, Inc. Files Form 10 with the Securities and Exchange Commission and Submits Nasdaq Application for Uplisting
Nasdaq listing aims to increase market visibility and global liquidity opportunities as BioStem advances its commercial and clinical initiatives amid record revenue growth Pompano Beach, FL, September 30, 2024 - PRISM MediaWire - BioStem Technologies, Inc. (OTC: BSEM) (“BioStem” or the “Company”), a leading MedTech company focused on the development, manufacture and commercialization of placental-derived biologics, announces the filing of a Form 10 registration statement (the “Registration...
Dr. Robert Langer, Co-Founder of Moderna, Joins Scientific Advisory Board of Klotho Neurosciences, Inc. (KLTO)
Renowned Biotech Leader to Contribute Expertise in Neuroscience and Therapeutics Development New York, NY, September 30, 2024 - PRISM MediaWire - Klotho Neurosciences, Inc. (NASDAQ: KLTO), a cutting-edge biotechnology company focused on developing innovative therapies for neurodegenerative diseases and promoting healthy longevity, is proud to announce that Dr. Robert Langer, co-founder of Moderna, has joined its Scientific Advisory Board. In addition to lending his world-class scientific...
PRISM MarketView Features Q&A with Dr. Michael Chancellor: Lipella Pharmaceuticals Advances Innovative Treatments for Hemorrhagic Cystitis During Urology Awareness Month
NEW YORK, September 25, 2024 - PRISM MediaWire - PRISM MarketView presents an exclusive Q&A with Dr. Michael Chancellor, Co-founder and Chief Medical Officer of Lipella Pharmaceuticals, Inc. (Nasdaq: LIPO). In this interview, Dr. Chancellor provides insights into the company's latest advancements in urological treatments, particularly in recognition of Urology Awareness Month, and discusses the significant progress made in the development of therapies for hemorrhagic cystitis (HC)....
Lipella Pharmaceuticals Reports Encouraging Early Tolerability Results in Phase 2a Trial of LP-310 for Oral Lichen Planus
PITTSBURGH, Sept. 24, 2024 – PRISM MediaWire - Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) (“Lipella” or the “Company”), a clinical-stage biotechnology company focused on addressing serious diseases with significant unmet needs, today announced an update on its ongoing multi-center Phase 2a clinical trial evaluating LP-310 for the treatment of Oral Lichen Planus (OLP). The Company reported that three participants have completed the four-week treatment with LP-310, an oral rinse, with...
Digital Utilities Ventures Reports Strong Fiscal Year 2024 – Advancing Leadership in Green Technologies
MANKATO, MN, September 23, 2024 - PRISM MediaWire - Digital Utilities Ventures, Inc. (OTC: DUTV), a leader in sustainable energy and environmental technologies, recently announced its financial results and corporate progress for the fiscal year ended May 31, 2024. The company demonstrated significant growth and strategic advancements, emphasizing its commitment to innovation and sustainable environment protecting technologies. Financial Highlights: Revenue Growth: The company reported net...
PRISM MarketView Showcases Aclarion: Disrupting Chronic Pain Treatment with Nociscan AI Technology
NEW YORK, September 13, 2024 - PRISM MediaWire - PRISM MarketView presents an exclusive Q&A with Brent Ness, CEO and Director of Aclarion, Inc. (Nasdaq: ACON). As a disruptive healthcare technology company focused on chronic low back pain, Aclarion is at the forefront of developing noninvasive tools to help physicians identify the source of pain in spinal discs, potentially revolutionizing the standard of care for this widespread and debilitating condition. Aclarion's Nociscan platform,...
Projetos de destaque da indústria de biocombustíveis no Brasil em 2024
Projetos de destaque da indústria de biocombustíveis no Brasil em 2024 Solicite a lista completa New York, September 2024 - PRISM MediaWire -Em preparação para o Fórum Internacional de Investimentos em Biocombustíveis Brasil 2024, a Vostock Capital preparou um relatório que inclui a lista completa dos projetos de destaque da indústria de biocombustíveis no Brasil, que serão abordados em detalhe durante o evento. Entre os projetos: EXPANSÃO DA PRODUÇÃO DE ETANOL Empresa: Atvos, Investimento:...
Proyectos emblemáticos de la industria de biocombustibles en Brasil 2024
Proyectos emblemáticos de la industria de biocombustibles en Brasil 2024 Solicite la lista completa New York, septiembre 2024 - PRISM MediaWire - Antes del Foro Internacional de Inversiones Biofuels Brazil 2024, Vostock Capital ha preparado un informe que presenta la lista completa de los proyectos emblemáticos de la industria de biocombustibles en Brasil, que se discutirán más a fondo en el evento. Entre los proyectos: • EXPANSIÓN DE PRODUCCIÓN DE ETANOL Empresa: Atvos, Inversión: US $920 M •...
Flagship projects of Biofuels industry in Brazil 2024
Flagship projects of Biofuels industry in Brazil 2024 Request the full list New York, September 2024 - PRISM MediaWire - Before International Investment Forum Biofuels Brazil 2024, Vostock Capital has prepared a report featuring the complete list of flagship projects of the Biofuels industry in Brazil, which will be further discussed at the event.Among the projects: ETHANOL PRODUCTION EXPANSION Company: Atvos, Investment: US $920 M CORN ETHANOL IN CAMPO MOURAO Company: Coamo...
Halberd Partnership Secures Contract from Defense Atomics Corporation to Address Brain Injury and PTSD
Contributing Funding and a Significant Additional Tool to Combat PTSD and TBI Jackson Center, PA., September 11, 2024 – PRISM MediaWire - Halberd Corporation (OTC PINK: HALB), in coordination with Athena Telemedicine Partners (ATP) and Athena GTX, Inc., is pleased to announce a substantial contract award commitment. Defense Atomics Corporation agreed to engage with the Halberd/Athena teams and to fund key advanced research, including the pending FDA IND study utilizing Halberd’s LDX technology...
Halberd Corp. Issues Letter to Shareholders – Patented LDN+ Evolves into WatchDawg™ for Veteran Suicide Reduction
Early Pilot Study Data from Veteran Volunteers is Compelling - Part B Jackson Center, PA September 9, 2024 – PRISM MediaWire - Halberd Corporation (OTC: HALB) today issued the following letter to its shareholders: We hope you have had an opportunity to check out last week’s Press release, Part A. This Part B supplements that release of a few days ago. As always reach out to us if you have any comments or thoughts. Good or bad, we appreciate them! The PTSD market is evolving. It is also...
Aclarion Added to PRISM Emerging Medical Devices Index
Company's industry-first technology addresses chronic low back pain Aclarion secured its first commercial agreement with Michigan's Sheridan Community Hospital PRISM Emerging Medical Devices Index features companies at forefront of innovation and market disruption in medtech NEW YORK, September 06, 2024 – PRISM MarketView, a leading provider of market insights and company news, is excited to announce that Aclarion, Inc. (NASDAQ: ACON) has been added to the PRISM Emerging Medical Devices Index,...